Brokerages forecast that Medpace Holdings Inc (NASDAQ:MEDP) will announce $0.39 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Medpace’s earnings, with estimates ranging from $0.37 to $0.41. Medpace posted earnings per share of $0.35 in the same quarter last year, which would suggest a positive year over year growth rate of 11.4%. The company is scheduled to issue its next earnings report on Monday, February 26th.
According to Zacks, analysts expect that Medpace will report full year earnings of $1.50 per share for the current financial year, with EPS estimates ranging from $1.49 to $1.52. For the next fiscal year, analysts forecast that the business will post earnings of $1.73 per share, with EPS estimates ranging from $1.67 to $1.84. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Medpace.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The business had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The company’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.40 EPS.
In other news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of Medpace stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total transaction of $138,736,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 25.80% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. Susquehanna International Group LLP boosted its stake in Medpace by 30.9% during the third quarter. Susquehanna International Group LLP now owns 9,947 shares of the company’s stock worth $317,000 after acquiring an additional 2,347 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Medpace by 173.8% during the third quarter. GSA Capital Partners LLP now owns 28,200 shares of the company’s stock worth $900,000 after acquiring an additional 17,900 shares in the last quarter. Convergence Investment Partners LLC boosted its stake in Medpace by 13.4% during the third quarter. Convergence Investment Partners LLC now owns 24,819 shares of the company’s stock worth $792,000 after acquiring an additional 2,940 shares in the last quarter. OxFORD Asset Management LLP boosted its stake in Medpace by 21.1% during the third quarter. OxFORD Asset Management LLP now owns 98,605 shares of the company’s stock worth $3,135,000 after acquiring an additional 17,161 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Medpace by 42.8% during the third quarter. Wells Fargo & Company MN now owns 10,354 shares of the company’s stock worth $330,000 after acquiring an additional 3,104 shares in the last quarter. 16.80% of the stock is currently owned by institutional investors and hedge funds.
Shares of Medpace (NASDAQ:MEDP) traded up $0.45 during trading on Friday, reaching $38.05. 152,900 shares of the company’s stock were exchanged, compared to its average volume of 212,250. The company has a market cap of $1,410.00 and a price-to-earnings ratio of 55.14. Medpace has a 1-year low of $21.76 and a 1-year high of $39.64. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68.
ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Medpace Holdings Inc (MEDP) Will Post Earnings of $0.39 Per Share” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2018/01/12/analysts-anticipate-medpace-holdings-inc-medp-will-post-earnings-of-0-39-per-share.html.
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.